



January 2024

VIA E-MAIL

Office of the Vermont Attorney General
Attention: Attorney General, Charity R. Clark
109 State Street
Montpelier, VT 05609
AGO.highcostprescriptiondrugs@vermont.gov

Dear Attorney General Clark:

This letter provides notice, pursuant to 18 VT. Stat. Ann. § 4637(b), that Coherus BioSciences, Inc. introduced to market in Vermont a new prescription drug, LOQTORZI (NDC 70114-0340-01), on December 12, 2023, at a wholesale acquisition cost above that of a specialty drug under the Medicare Part D program. LOQTORZI was granted breakthrough therapy designation (but not priority review) by the US Food and Drug Administration prior to final approval.

Pursuant to 18 V.S.A. § 4637(d), this notice includes all information that is in the public domain or publicly available.

If you have any questions or comments, please let me know.

Thank you,

DocuSigned by:

A handwritten signature in black ink that reads "Claudia Martinez".

D9CB3EB911A5421...

Claudia Martinez

Sr. Director Government Pricing & Rebate Processing

Coherus BioSciences, Inc.
333 Twin Dolphin Dr., Suite 600,
Redwood City, CA 94065

E-mail: clmartinez@coherus.com | Office Phone: 650-395-0169